When Stéphane Bancel left his job at a French medical diagnostics firm to join Moderna in 2011, he told his wife he thought the new job had only a “5% chance” of working out, says The Sunday Times. Moderna then was a heavily loss-making fledgling start-up, majoring on an experimental and unproven technology – messenger RNA. Yet a decade and a deadly virus on, it’s clear his career gamble has paid off. As one associate observes, “the pandemic came almost as a blessing to prove the technology”.
Big, hairy, audacious goals
The Boston-based company was the first in America to begin trials of a vaccine based on mRNA (the same gene-based approach used by Germany’s BioNTech) and has since become “one of the leaders in the fight against Covid-19”. Unlike AstraZeneca – an early investor which has rolled out its own vaccine at cost – Moderna is making “serious money from its contribution”, charging between $33 and $37 per dose as it distributes hundreds of millions of jabs worldwide. Since mid-March 2020, its shares have risen by more than 500%, taking its stockmarket value to $57bn. Its French boss, who has an 8% stake, is now worth an estimated $4.6bn.
The challenge of producing a vaccine from scratch in double-quick time was meat and drink to Bancel, 48, who thrives on setting himself ambitious challenges, says the Financial Times. Long before the virus even had a name, Bancel spent his Christmas break tracking its movements in China. According to Moderna’s second-in-command, Stephen Hoge, who has worked with him almost since Moderna’s inception, quite often Bancel would outline some “big, hairy, audacious goal… and I’m like, ‘I don’t know what planet you’re on’. He’s... expansive in his thinking”. Unusually for a biotech chief, he’s an engineer, not a biologist. The point, says a former colleague, is that “he has this capacity to work like a dog... to learn about science”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Born in 1972, Bancel grew up in Marseilles and might be described as the perfect professional amalgam of his parents – his father was an engineer and his mother a doctor. Bancel had a “precocious interest in maths and science” and “tinkered with computers” as a child, notes a 2016 Harvard Innovation Labs profile. He “imagined he would one day work in technology”. After studying chemical and biomolecular engineering at École Centrale Paris, Bancel moved to the US to do a masters in biological engineering at Minnesota University. His first job was at diagnostics firm BioMérieux, which sponsored an MBA at Harvard Business School. At 29, he joined the US pharmaceuticals firm Eli Lilly, before returning to lead BioMérieux when he was just 34. A few years later, he took his gamble with Moderna.
The Amazon of mRNA
“Bancel attributes a great deal of his success as an executive to the breadth of the liberal arts education he received in France.” Others think it owes more to Silicon Valley. A “master fundraiser” in the days before Moderna’s blockbusting 2018 float, he used to talk about admiring Uber’s “platform” strategy, says the FT. Some of Uber boss Travis Kalanick’s controversial modus operandi may have rubbed off too. Moderna’s “hard-charging culture shook some former employees used to working at biotechs that operate more like academia”. His ambition hasn’t changed: he still wants to make Moderna, which has 23 products in development, “the Amazon of mRNA”.
-
NS&I cuts interest rates on two easy-access savings accounts – are they still worth it?NS&I has announced more interest rate cuts, just weeks after launching less attractive rates on fixed-term British Savings Bonds
-
Hargreaves Lansdown shakes up fees in biggest change in 10 years – what does it mean for you?Hargreaves Lansdown is lowering its headline fee from 0.45% to 0.35% – but not everyone will be happy with the new fee structure, it’s been suggested.
-
Michael Moritz: the richest Welshman to walk the EarthMichael Moritz started out as a journalist before catching the eye of a Silicon Valley titan. He finds Donald Trump to be “an absurd buffoon”
-
David Zaslav, Hollywood’s anti-hero dealmakerWarner Bros’ boss David Zaslav is embroiled in a fight over the future of the studio that he took control of in 2022. There are many plot twists yet to come
-
The rise and fall of Nicolás Maduro, Venezuela's ruthless dictatorNicolás Maduro is known for getting what he wants out of any situation. That might be a challenge now
-
The political economy of Clarkson’s FarmOpinion Clarkson’s Farm is an amusing TV show that proves to be an insightful portrayal of political and economic life, says Stuart Watkins
-
The most influential people of 2025Here are the most influential people of 2025, from New York's mayor-elect Zohran Mamdani to Japan’s Iron Lady Sanae Takaichi
-
Luana Lopes Lara: The ballerina who made a billion from prediction marketsLuana Lopes Lara trained at the Bolshoi, but hung up her ballet shoes when she had the idea of setting up a business in the prediction markets. That paid off
-
Who is Christopher Harborne, crypto billionaire and Reform UK’s new mega-donor?Christopher Harborne came into the spotlight when it emerged he had given £9 million to Nigel Farage's Reform UK. How did he make his millions?
-
Why Trustpilot is a stock to watch for exposure to the e-commerce marketTrustpilot has built a defensible position in one of the most critical areas of the internet: the infrastructure of trust, says Jamie Ward
